Hilal Susam-Sen, Ali Varan, İnci Bajin, Rahşan Göçmen, Burca Aydın, Bilgehan Yalcin, Nilgun Kurucu, Tezer Kutluk, Turhan Bayhan, Canan Akyuz
Relapsed or refractory central nervous system (CNS) tumors still have poor prognosis, and, therefore, new treatment options are required. We retrospectively researched treatment results of patients with CNS tumors treated with nimotuzumab from 2010 to 2015. The study included nine patients with the diffuse intrinsic pontine glioma; eight with medulloblastoma; three each with anaplastic ependymoma, glioblastoma multiforme, and central nervous system primitive neuroectodermal tumor (CNS PNET); two patients with gliomatosis cerebri; and one patient each with other tumor types, including atypical teratoid rhabdoid tumor, thalamic astrocytoma, low-grade glial tumor, high-grade glial tumor, and cribriform neuroepithelial tumor...
June 21, 2021: Naunyn-Schmiedeberg's Archives of Pharmacology